Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: April 9, 2009
Last updated: May 12, 2011
Last verified: May 2011

The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.

Condition Intervention Phase
Advanced Solid Tumors
Biological: CVX-060
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, And Pharmacodynamic Trial Of CVX-060, A Selective Angiopoietin-2 (ANG-2) Binding, Anti-Angiogenic COVX-Body, In Patients With Advanced Solid Tumors

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • To determine safety and tolerability of CVX-060 as weekly intravenous (IV) infusions in adult patients with advanced solid tumors [ Time Frame: Throughout duration of study ] [ Designated as safety issue: Yes ]
  • To identify and characterize CVX-060-related adverse events (AEs) [ Time Frame: Throughout duration of study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To evaluate the plasma pharmacokinetics (PK) of CVX-060 [ Time Frame: Days 0, 4, 7, 14, 28 ] [ Designated as safety issue: Yes ]
  • To determine a recommended Phase 2 dose of CVX-060 [ Time Frame: End of study ] [ Designated as safety issue: No ]
  • To evaluate the potential for immunogenicity of CVX-060 [ Time Frame: Day 0, 14, 1st day of each cycle, EOS, 42 Day FU ] [ Designated as safety issue: Yes ]
  • To document any preliminary evidence of antitumor activity [ Time Frame: Every 8 weeks ] [ Designated as safety issue: No ]

Enrollment: 34
Study Start Date: January 2008
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Biological: CVX-060
Weekly, intravenous dose


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed advanced solid tumors unresponsive to currently available therapies or for which there is no standard therapy.
  • Adequate coagulation, liver, and renal function.
  • Candidate for DCE-MRI evaluations.
  • ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.

Exclusion Criteria:

  • Evidence of significant bleeding problems.
  • History of certain gastrointestinal problems including fistula and abscess.
  • Chronic, uncontrolled hypertension.
  • Patients with any history of primary or metastatic tumor involvement of the brain or with tumors that encase great vessels.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00879684

United States, Arizona
Pfizer Investigational Site
Scottsdale, Arizona, United States, 85258
Pfizer Investigational Site
Scottsdale, Arizona, United States, 85255
United States, California
Pfizer Investigational Site
Santa Monica,, California, United States, 90404
United States, Pennsylvania
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19111
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00879684     History of Changes
Other Study ID Numbers: B1131002, CVX-060-101
Study First Received: April 9, 2009
Last Updated: May 12, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Phase 1

Additional relevant MeSH terms:
Neoplasms processed this record on November 27, 2014